Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy (STOP)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2012 by NovaRx Corporation.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
NovaRx Corporation
ClinicalTrials.gov Identifier:
NCT00676507
First received: May 8, 2008
Last updated: May 29, 2012
Last verified: May 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: October 2012
  Estimated Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Publications: